Platform capabilities, scientific publications, and technical documentation
SentinusAI® is a de novo antibody and fusion protein engineering AI platform that designs and optimizes candidates based solely on the target sequence, delivering computational results within a week and optimized drug candidates within a month.
IgG, Fab, scFv, VHH, peptides, bispecific and multi-specific formats, ADC/PDC
Therapeutic antibody affinity maturation, fusion protein engineering
Immunogenicity assessment, antibody humanization
Binding specificity optimization
Protein off-target toxicity prediction
Stability prediction and sequence optimization
Peer-reviewed publication in Nature Scientific Reports demonstrating AI-designed, mutation resistant broad neutralizing antibodies against multiple SARS-CoV-2 strains.
Published research on AI-powered antibody design methodology and validation results available through PubMed Central.
De novo antibody and fusion protein engineering AI platform. Designs and optimizes candidates from target sequence alone.
Small-molecule, PROTAC and pocket discovery from sequence alone. Enables traditional drug modality design with AI.
Multi-epitope cell therapy design for CAR-T and other cell-based therapeutics.
Affinity maturation or de novo sequence generation; ranked candidate list; developability assessments.
Gene synthesis, cloning, CHO cell expression, purification, QC. 50 samples (200 µg – 1 mg each).
BLI-Gator/Octet or SPR/Biacore detection. Single-dose ranking or full KD measurement.
Sequence optimization / affinity maturation – Starting from existing VH/VL sequences with ~50 variants per round. Typical hit rates: ~10% (Round 1), 40% (Round 2), 60% (Round 3). De novo design – For novel or hard-to-express targets, generating ~50 de novo antibody sequences directly from the antigen sequence.
Computational phase: ~1 week per iteration. Protein expression & testing: ~2 weeks per batch. Total project cycle: 1–3 months, depending on the number of design–test iterations.
For affinity maturation: VH/VL sequences, target (antigen) sequence. For de novo design: Target sequence alone is sufficient. 3D structures are helpful but not mandatory—our AI can perform in-silico epitope mapping from sequence alone.
No. Ainnocence's discovery platform is a proprietary, sequence-based AI system developed entirely in-house. By working directly from primary sequence data, it eliminates the need for external 3D structure-prediction software, evaluating up to 10¹⁰ candidates within hours to days.
Contact our team to discuss your specific therapeutic or diagnostic targets and learn how SentinusAI® can accelerate your discovery program.
Learn more about the full Ainnocence technology stack and explore additional platforms including CarbonAI™ and CellulaAI™.